NZ538296A - Indole derivatives or benzimidazole derivatives for modulating IkB kinase - Google Patents

Indole derivatives or benzimidazole derivatives for modulating IkB kinase

Info

Publication number: NZ538296A
Authority: NZ; New Zealand
Prior art keywords: alkyl; compound; formula; indole; carboxamide
Prior art date: 2002-08-17

Application number

NZ538296A

Other languages

English (en)

Inventor

Olaf Ritzeler

Gerhard Jaehne

Original Assignee

Sanofi Aventis Deutschland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-17

Filing date

2003-08-05

Publication date

2007-03-30

2003-08-05 Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland

2007-03-30 Publication of NZ538296A publication Critical patent/NZ538296A/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Rheumatology (AREA)
Virology (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Tropical Medicine & Parasitology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Hematology (AREA)
Psychiatry (AREA)
AIDS & HIV (AREA)

NZ538296A 2002-08-17 2003-08-05 Indole derivatives or benzimidazole derivatives for modulating IkB kinase NZ538296A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10237722A DE10237722A1 (de)	2002-08-17	2002-08-17	Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
PCT/EP2003/008629 WO2004022553A1 (de)	2002-08-17	2003-08-05	INDOL-ODER BENZIMIDAZOLDERIVATE ZUR MODULATION DER IλB-KINASE

Publications (1)

Publication Number	Publication Date
NZ538296A true NZ538296A (en)	2007-03-30

Family

ID=31968974

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NZ538296A NZ538296A (en)	2002-08-17	2003-08-05	Indole derivatives or benzimidazole derivatives for modulating IkB kinase

Country Status (43)

Country	Link
US (2)	US7285560B2 (el)
EP (2)	EP1530568B1 (el)
JP (1)	JP4504812B2 (el)
KR (1)	KR101162046B1 (el)
CN (1)	CN1314683C (el)
AR (1)	AR040975A1 (el)
AT (2)	ATE557018T1 (el)
AU (1)	AU2003263196B2 (el)
BR (1)	BR0313562A (el)
CA (1)	CA2498559C (el)
CO (1)	CO5690586A2 (el)
CR (1)	CR7668A (el)
CY (2)	CY1111692T1 (el)
DE (2)	DE10237722A1 (el)
DK (2)	DK1530568T3 (el)
EC (1)	ECSP055612A (el)
ES (2)	ES2387954T3 (el)
HK (1)	HK1079509A1 (el)
HN (1)	HN2003000249A (el)
HR (1)	HRP20050042B1 (el)
IL (1)	IL166785A0 (el)
JO (1)	JO2764B1 (el)
MA (1)	MA27382A1 (el)
ME (1)	MEP60608A (el)
MX (1)	MXPA05001314A (el)
MY (1)	MY140074A (el)
NO (1)	NO330981B1 (el)
NZ (1)	NZ538296A (el)
OA (1)	OA12908A (el)
PA (1)	PA8580501A1 (el)
PE (1)	PE20040893A1 (el)
PL (1)	PL374229A1 (el)
PT (2)	PT2233483E (el)
RS (1)	RS51902B (el)
RU (1)	RU2318820C2 (el)
SI (2)	SI1530568T1 (el)
SV (1)	SV2004001599A (el)
TN (1)	TNSN05045A1 (el)
TW (1)	TWI290552B (el)
UA (1)	UA78591C2 (el)
UY (1)	UY27941A1 (el)
WO (1)	WO2004022553A1 (el)
ZA (1)	ZA200500322B (el)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19951360A1 (de) *	1999-10-26	2001-05-03	Aventis Pharma Gmbh	Substituierte Indole
DE10237723A1 (de) *	2002-08-17	2004-07-08	Aventis Pharma Deutschland Gmbh	Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
DE10237722A1 (de) *	2002-08-17	2004-08-19	Aventis Pharma Deutschland Gmbh	Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
KR20110010824A (ko)	2003-01-14	2011-02-07	아레나 파마슈티칼스, 인크.	대사 조절제로서의 １,２,３-삼치환된 아릴 및 헤테로아릴 유도체, 및 당뇨병 및 고혈당증을 비롯한 이에 관련된 장애의 예방 및 치료
AR045047A1 (es) *	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
BRPI0511029A (pt) *	2004-05-12	2007-11-27	Aventis Pharma Inc	ácido 2-{[2-(2-metil amino-pirimidin-4-il)-1h-indol-5-carbonil]-amino}-3-(feni l piridin-2-il-amino)-propiÈnico substancialmente puro como um inibidor da i capa b quinase
PE20060373A1 (es)	2004-06-24	2006-04-29	Smithkline Beecham Corp	Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2
DE102004033406A1 (de)	2004-07-10	2006-02-16	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung der enantiomeren Formen von 2,3-Diaminopropionsäurederivaten
PE20060748A1 (es)	2004-09-21	2006-10-01	Smithkline Beecham Corp	Derivados de indolcarboxamida como inhibidores de quinasa ikk2
DOP2006000010A (es) *	2005-01-10	2006-07-31	Arena Pharm Inc	Procedimiento para preparar eteres aromáticos
AR053114A1 (es) *	2005-01-12	2007-04-25	Aventis Pharma Inc	Sal monopotasica del acido 2-{[2-(-2-metilamino-pirimidin-4-il)-1h-indol-5-carbonil]-amino}-3-(fenilpiridin-2-il-amino)-propionico,inhibidora de ikk-2 quinasa
US20070142417A1 (en) *	2005-05-11	2007-06-21	Aventis Pharmaceuticals Inc	Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor
DE102005025225A1 (de)	2005-06-01	2006-12-07	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten
KR20080021077A (ko)	2005-06-30	2008-03-06	스미스클라인 비참 코포레이션	화합물
US8063071B2 (en)	2007-10-31	2011-11-22	GlaxoSmithKline, LLC	Chemical compounds
US8093401B2 (en) *	2005-08-04	2012-01-10	Sirtris Pharmaceuticals, Inc.	Sirtuin modulating compounds
US8088928B2 (en) *	2005-08-04	2012-01-03	Sirtris Pharmaceuticals, Inc.	Sirtuin modulating compounds
US7855289B2 (en) *	2005-08-04	2010-12-21	Sirtris Pharmaceuticals, Inc.	Sirtuin modulating compounds
CA2617532A1 (en)	2005-08-04	2007-02-15	Sirtris Pharmaceuticals, Inc.	Imidazo [2,1-b] thiazole derivatives as sirtuin modulating compounds
WO2007030362A1 (en)	2005-09-07	2007-03-15	Laboratoires Serono Sa.	Ikk inhibitors for the treatment of endometriosis
JP2009001495A (ja) *	2005-10-13	2009-01-08	Taisho Pharmaceutical Co Ltd	２−アリール−ベンゾイミダゾール−５−カルボキサミド誘導体
BRPI0715160A2 (pt)	2006-08-08	2013-06-11	Sanofi Aventis	imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
AR065804A1 (es)	2007-03-23	2009-07-01	Smithkline Beecham Corp	Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
CL2008001822A1 (es) *	2007-06-20	2009-03-13	Sirtris Pharmaceuticals Inc	Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20110039847A1 (en) *	2007-11-01	2011-02-17	Sirtris Pharmaceuticals, Inc	Amide derivatives as sirtuin modulators
JP2011503066A (ja) *	2007-11-08	2011-01-27	サートリスファーマシューティカルズ，インコーポレイテッド	可溶化チアゾロピリジン誘導体
UY31968A (es)	2008-07-09	2010-01-29	Sanofi Aventis	Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
UA104447C2 (uk)	2008-12-19	2014-02-10	Сіртріз Фармасьютікалз, Інк.	Тіазолопіридинові сполуки, що модулюють сиртуїн
MX2011008982A (es) *	2009-02-27	2011-09-15	Enata Pharmaceuticals Inc	Inhibidores del virus de la hepatitis c.
WO2010102968A1 (en)	2009-03-10	2010-09-16	Glaxo Group Limited	Indole derivatives as ikk2 inhibitors
US8785608B2 (en)	2009-08-26	2014-07-22	Sanofi	Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP3378854B1 (en)	2010-01-27	2022-12-21	Arena Pharmaceuticals, Inc.	Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
MX2012012502A (es) *	2010-04-27	2013-01-18	Hutchison Medipharma Ltd	Compuestos pirimidinil indol.
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
EP2603491B1 (en) *	2010-08-12	2014-09-24	Sanofi	Process for the preparation of enantiomeric forms of 2,3-diaminopropionic acid derivatives
US10894787B2 (en)	2010-09-22	2021-01-19	Arena Pharmaceuticals, Inc.	Modulators of the GPR119 receptor and the treatment of disorders related thereto
TW201242962A (en) *	2010-12-01	2012-11-01	Sumitomo Chemical Co	Pyrimidine compound and use for pest control thereof
WO2012120052A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de)	2011-03-08	2012-09-13	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de)	2011-03-08	2012-09-13	Sanofi	Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809324B2 (en)	2011-03-08	2014-08-19	Sanofi	Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8895547B2 (en)	2011-03-08	2014-11-25	Sanofi	Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120058A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de)	2011-03-08	2015-04-22	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en)	2011-03-08	2014-10-28	Sanofi	Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683698B1 (de)	2011-03-08	2017-10-04	Sanofi	Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP5427321B2 (ja)	2011-07-27	2014-02-26	アストラゼネカアクチボラグ	２−（２，４，５−置換−アニリノ）ピリミジン化合物
CN103930404B (zh) *	2011-08-25	2016-08-24	圣朱德儿童研究医院	用于抗疟疾治疗方法的取代的2-烷基-1-氧代-n-苯基-3-杂芳基-1,2,3,4-四氢异喹啉-4-酰胺
WO2013045413A1 (en)	2011-09-27	2013-04-04	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9067918B2 (en) *	2011-12-06	2015-06-30	Sanofi	Crystalline forms of 2-(2-methylamino-pyrimidin-4-yl)-1H-indole-5-carboxylic acid [ (S)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl ]-amide
EA036521B1 (ru) *	2012-01-27	2020-11-19	Астразенека Аб	Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака
KR101493877B1 (ko)	2013-03-29	2015-02-16	농업회사법인 주식회사 생명의나무	스피나스테롤 당 유도체를 포함하는 골 질환 예방 또는 치료용 약학 조성물
EP2805705B1 (en)	2013-05-23	2016-11-09	IP Gesellschaft für Management mbH	Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid
EP2905282A1 (en) *	2014-02-05	2015-08-12	AXXAM S.p.A.	Substituted thiazole or oxazole as P2X7 receptor antagonists
CN106535899A (zh)	2014-07-03	2017-03-22	赛诺菲	用于治疗与骨关节炎相关的疼痛的2‑(2‑甲基氨基‑嘧啶‑4‑基)‑1h‑吲哚‑5‑甲酸[(s)‑1‑氨甲酰基‑2‑(苯基‑嘧啶‑2‑基‑氨基)‑乙基]‑酰胺
MX2021011472A (es)	2015-01-06	2022-08-17	Arena Pharm Inc	Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
KR102603199B1 (ko)	2015-06-22	2023-11-16	아레나 파마슈티칼스, 인크.	Ｓ1ｐ1 수용체-관련 장애에서의 사용을 위한 (ｒ)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[ｂ]인돌-3-일)아세트산 (화합물 1)의 결정성 ｌ-아르기닌 염
EP3290416A1 (en) *	2016-08-31	2018-03-07	AXXAM S.p.A.	Substituted n-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide and n-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide derivatives and their use as p2x7 receptor antagonist
CN106588803A (zh) *	2016-11-16	2017-04-26	西南科技大学	一种制备5‑乙酰基异噁唑的新方法
CN108299302A (zh) *	2017-01-11	2018-07-20	西南科技大学	一种制备3-乙酰基吡唑的新方法
WO2018151873A1 (en)	2017-02-16	2018-08-23	Arena Pharmaceuticals, Inc.	Compounds and methods for treatment of primary biliary cholangitis
JP2023512647A (ja) *	2020-01-30	2023-03-28	アニマバイオテックインコーポレイテッド	コラーゲン１翻訳阻害剤およびその使用方法
CN115974849A (zh) *	2022-12-28	2023-04-18	中国药科大学	一种吲哚氧乙酰胺类衍生物、包含其的药物组合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5559127A (en)	1992-10-14	1996-09-24	Merck & Co., Inc.	Fibrinogen receptor antagonists
GB9225141D0 (en)	1992-12-01	1993-01-20	Smithkline Beecham Corp	Chemical compounds
IT1275433B (it) *	1995-05-19	1997-08-07	Smithkline Beecham Farma	Derivati di diarildiammine
ME00370B (me)	1999-06-23	2011-05-10	Sanofi Aventis Deutschland	SUPSTITUISANI BENZIMIDAZOLl
DE19951360A1 (de) *	1999-10-26	2001-05-03	Aventis Pharma Gmbh	Substituierte Indole
WO2002060386A2 (en)	2001-02-01	2002-08-08	Bristol-Myers Squibb Company	METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF IλB KINASE (IKK)
DE10237723A1 (de) *	2002-08-17	2004-07-08	Aventis Pharma Deutschland Gmbh	Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
DE10237722A1 (de) *	2002-08-17	2004-08-19	Aventis Pharma Deutschland Gmbh	Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US7462638B2 (en) *	2002-08-17	2008-12-09	Sanofi-Aventis Deutschland Gmbh	Use of IκB-kinase inhibitors in pain therapy
US7046741B2 (en) *	2004-04-16	2006-05-16	Data Flow Technologies, Inc.	Single and multiple sinewave modulation and demodulation techniques, apparatus, and communications systems

2002
- 2002-08-17 DE DE10237722A patent/DE10237722A1/de not_active Withdrawn
2003
- 2003-05-08 UA UAA200502387A patent/UA78591C2/uk unknown
- 2003-07-23 JO JO200387A patent/JO2764B1/en active
- 2003-08-05 AT AT10163200T patent/ATE557018T1/de active
- 2003-08-05 NZ NZ538296A patent/NZ538296A/en not_active IP Right Cessation
- 2003-08-05 WO PCT/EP2003/008629 patent/WO2004022553A1/de active Application Filing
- 2003-08-05 KR KR1020057002707A patent/KR101162046B1/ko not_active IP Right Cessation
- 2003-08-05 ES ES10163200T patent/ES2387954T3/es not_active Expired - Lifetime
- 2003-08-05 OA OA1200500047A patent/OA12908A/en unknown
- 2003-08-05 RU RU2005107418/04A patent/RU2318820C2/ru not_active IP Right Cessation
- 2003-08-05 DK DK03793685.3T patent/DK1530568T3/da active
- 2003-08-05 CN CNB038195437A patent/CN1314683C/zh not_active Expired - Fee Related
- 2003-08-05 RS YU20050104A patent/RS51902B/sr unknown
- 2003-08-05 CA CA2498559A patent/CA2498559C/en not_active Expired - Fee Related
- 2003-08-05 AT AT03793685T patent/ATE493402T1/de active
- 2003-08-05 MX MXPA05001314A patent/MXPA05001314A/es active IP Right Grant
- 2003-08-05 AU AU2003263196A patent/AU2003263196B2/en not_active Ceased
- 2003-08-05 PT PT10163200T patent/PT2233483E/pt unknown
- 2003-08-05 DE DE50313372T patent/DE50313372D1/de not_active Expired - Lifetime
- 2003-08-05 SI SI200331971T patent/SI1530568T1/sl unknown
- 2003-08-05 PT PT03793685T patent/PT1530568E/pt unknown
- 2003-08-05 EP EP03793685A patent/EP1530568B1/de not_active Expired - Lifetime
- 2003-08-05 DK DK10163200.8T patent/DK2233483T3/da active
- 2003-08-05 PL PL03374229A patent/PL374229A1/xx unknown
- 2003-08-05 JP JP2004533319A patent/JP4504812B2/ja not_active Expired - Fee Related
- 2003-08-05 ES ES03793685T patent/ES2358795T3/es not_active Expired - Lifetime
- 2003-08-05 BR BRPI0313562-4A patent/BR0313562A/pt not_active Application Discontinuation
- 2003-08-05 SI SI200332173T patent/SI2233483T1/sl unknown
- 2003-08-05 PE PE2003000772A patent/PE20040893A1/es not_active Application Discontinuation
- 2003-08-05 ME MEP-606/08A patent/MEP60608A/xx unknown
- 2003-08-05 EP EP10163200A patent/EP2233483B1/de not_active Expired - Lifetime
- 2003-08-12 PA PA20038580501A patent/PA8580501A1/es unknown
- 2003-08-14 TW TW092122309A patent/TWI290552B/zh not_active IP Right Cessation
- 2003-08-14 AR ARP030102946A patent/AR040975A1/es not_active Application Discontinuation
- 2003-08-15 SV SV2003001599A patent/SV2004001599A/es unknown
- 2003-08-15 UY UY27941A patent/UY27941A1/es unknown
- 2003-08-15 MY MYPI20033115A patent/MY140074A/en unknown
- 2003-08-15 HN HN2003000249A patent/HN2003000249A/es unknown
- 2003-08-18 US US10/642,970 patent/US7285560B2/en active Active
2005
- 2005-01-13 ZA ZA200500322A patent/ZA200500322B/en unknown
- 2005-01-14 HR HRP20050042AA patent/HRP20050042B1/hr not_active IP Right Cessation
- 2005-01-28 CR CR7668A patent/CR7668A/es unknown
- 2005-02-09 IL IL16678505A patent/IL166785A0/xx not_active IP Right Cessation
- 2005-02-15 MA MA28106A patent/MA27382A1/fr unknown
- 2005-02-15 CO CO05013335A patent/CO5690586A2/es active IP Right Grant
- 2005-02-16 TN TNP2005000045A patent/TNSN05045A1/en unknown
- 2005-02-17 EC EC2005005612A patent/ECSP055612A/es unknown
- 2005-03-15 NO NO20051337A patent/NO330981B1/no not_active IP Right Cessation
- 2005-12-12 HK HK05111392A patent/HK1079509A1/xx not_active IP Right Cessation
2007
- 2007-06-06 US US11/758,978 patent/US8778955B2/en not_active Expired - Fee Related
2011
- 2011-03-02 CY CY20111100246T patent/CY1111692T1/el unknown
2012
- 2012-07-24 CY CY20121100658T patent/CY1112991T1/el unknown

Also Published As

Publication number	Publication date
IL166785A0 (en)	2006-01-15
CN1314683C (zh)	2007-05-09
CO5690586A2 (es)	2006-10-31
JO2764B1 (en)	2014-03-15
UY27941A1 (es)	2004-03-31
SV2004001599A (es)	2004-02-26
AU2003263196B2 (en)	2009-01-22
NO330981B1 (no)	2011-08-29
ZA200500322B (en)	2006-07-26
ES2358795T3 (es)	2011-05-13
WO2004022553A1 (de)	2004-03-18
HK1079509A1 (en)	2006-04-07
JP2005539054A (ja)	2005-12-22
ATE493402T1 (de)	2011-01-15
EP1530568A1 (de)	2005-05-18
DK2233483T3 (da)	2012-08-20
US8778955B2 (en)	2014-07-15
PT2233483E (pt)	2012-07-20
PT1530568E (pt)	2011-02-23
PL374229A1 (en)	2005-10-03
TW200418832A (en)	2004-10-01
CA2498559C (en)	2012-01-24
CY1111692T1 (el)	2015-10-07
US20070244139A1 (en)	2007-10-18
HRP20050042A2 (en)	2006-03-31
OA12908A (en)	2006-10-13
CY1112991T1 (el)	2016-04-13
SI2233483T1 (sl)	2012-08-31
US7285560B2 (en)	2007-10-23
AR040975A1 (es)	2005-04-27
EP1530568B1 (de)	2010-12-29
RU2005107418A (ru)	2005-08-27
MEP60608A (en)	2011-05-10
EP2233483A1 (de)	2010-09-29
KR20050058338A (ko)	2005-06-16
HRP20050042B1 (hr)	2013-09-30
AU2003263196A1 (en)	2004-03-29
US20050197353A1 (en)	2005-09-08
MXPA05001314A (es)	2005-04-28
MY140074A (en)	2009-11-30
HN2003000249A (es)	2008-08-06
PE20040893A1 (es)	2004-12-21
PA8580501A1 (es)	2004-04-23
BR0313562A (pt)	2006-06-13
RU2318820C2 (ru)	2008-03-10
RS51902B (sr)	2012-02-29
DE10237722A1 (de)	2004-08-19
RS20050104A (en)	2007-06-04
CR7668A (es)	2009-03-11
TWI290552B (en)	2007-12-01
ATE557018T1 (de)	2012-05-15
DK1530568T3 (da)	2011-04-18
UA78591C2 (en)	2007-04-10
JP4504812B2 (ja)	2010-07-14
ES2387954T3 (es)	2012-10-04
KR101162046B1 (ko)	2012-07-04
ECSP055612A (es)	2005-04-18
DE50313372D1 (de)	2011-02-10
CA2498559A1 (en)	2004-03-18
TNSN05045A1 (en)	2007-05-14
SI1530568T1 (sl)	2011-05-31
EP2233483B1 (de)	2012-05-09
NO20051337L (no)	2005-05-03
CN1675196A (zh)	2005-09-28
MA27382A1 (fr)	2005-06-01

Legal Events

Date	Code	Title	Description
2007-07-27	ASS	Change of ownership	Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, DE Free format text: OLD OWNER(S): SANOFI-AVENTIS DEUTSCHLAND GMBH
2007-07-27	PSEA	Patent sealed
2007-08-31	RENW	Renewal (renewal fees accepted)
2010-08-27	RENW	Renewal (renewal fees accepted)
2013-06-28	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 05 AUG 2016 BY CPA GLOBAL Effective date: 20130621
2017-02-24	LAPS	Patent lapsed

Publication	Publication Date	Title
CA2498559C (en)	2012-01-24	Indole derivatives or benzimidazole derivatives for modulating i.kappa.b kinase
JP3843012B2 (ja)	2006-11-08	ＮＦκＢ活性を調節するための置換インドール
JP5487214B2 (ja)	2014-05-07	キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物
JP2006510672A (ja)	2006-03-30	プラスミノーゲン活性化因子の阻害因子−１（ｐａｉ−１）の阻害剤としての置換インドールオキソ−アセチルアミノ酢酸誘導体
JP2008266295A (ja)	2008-11-06	キナーセ゛阻害活性を有する新規チアシ゛アソ゛ール誘導体
TW200533659A (en)	2005-10-16	Acylaminothiazole derivatives, their preparation and their therapeutic application
EP1270569A1 (en)	2003-01-02	Substituted tryptophan derivatives
FR2951169A1 (fr)	2011-04-15	Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
FR2947547A1 (fr)	2011-01-07	Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb)